Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Vanda Pharmaceuticals

02/05/2025 13:34

Vanda Pharmaceuticals Inc VNDA.OQ VNDA.O is expected to show a fall in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Washington Washington Dc-based  company is expected to report a 4.9% decrease in revenue to $45.134 million from $47.46 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vanda Pharmaceuticals Inc is for a loss of 60 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $13.00​, above​ its last closing price of $4.44. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.11
-0.11
-0.08
Beat
25
Sep. 30 2024
-0.16
-0.16
-0.09
Beat
44.9
Jun. 30 2024
-0.21
-0.21
-0.08
Beat
61.9​
-0.07
​​Dec. 31 2023
-0.09
-0.09
-0.04
Beat
55.6
Sep. 30 2023
-0.04
-0.04
0.00
Beat
100​
Jun. 30 2023
-0.13
-0.13
0.03
Beat
123.1

This summary was machine generated May 2 at 12:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)